Clovis Oncology Inc. Stock
€0.077
Your prediction
Clovis Oncology Inc. Stock
Pros and Cons of Clovis Oncology Inc. in the next few years
Pros
Cons
Performance of Clovis Oncology Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Clovis Oncology Inc. | -6.090% | 0.000% | 0.000% | -95.821% | 0.000% | -98.668% | -99.821% |
Sorrento Therapeutics Inc. | -24.520% | 0.000% | 0.000% | -86.746% | -65.296% | -83.166% | - |
Evolus Inc | 1.960% | 1.961% | -5.455% | -26.415% | 10.638% | 103.125% | - |
Hepion Pharmaceuticals Inc. | 1.850% | 13.615% | -12.460% | -39.283% | 161.013% | -53.529% | - |
Comments
News

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis